Merck Announces Fourth-Quarter 2012 Sales and Earnings Conference Call
WHITEHOUSE STATION, N.J. -- January 2, 2013
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will
hold its fourth-quarter 2012 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EST on Friday, Feb. 1.
During the call, Kenneth C. Frazier, chairman and chief executive officer;
Peter N. Kellogg, executive vice president and chief financial officer; and
Adam H. Schechter, president, Global Human Health, will provide an overview of
Merck’s financial performance for the quarter.
Investors, journalists and the general public may access a live audio webcast
of the call on Merck’s website at
needed to listen to the webcast is available on the corporate website and
should be downloaded prior to the beginning of the webcast. A replay of the
webcast will be available at approximately 11:00 a.m. EST on Feb. 1 and will
remain on the website for 12 months. The quarter's sales and earnings news
release and supplemental financial disclosures also will be available in the
Newsroom and Investor sections of the company's website at www.merck.com.
Members of the media are invited to monitor the call by dialing (706) 758-9928
or (800) 399-7917 and using ID code number 81283478. Journalists who wish to
ask questions are requested to contact a member of Merck's Media Relations
team at the conclusion of the call.
Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and
connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck’s
patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2011
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
Ron Rogers, 908-423-6449
Carol Ferguson, 908-423-4465
Press spacebar to pause and continue. Press esc to stop.